Axsome Therapeutics (AXSM) EBIAT (2022 - 2025)
Historic EBIAT for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.
- Axsome Therapeutics' EBIAT rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 2618.64%. This contributed to the annual value of -$287.2 million for FY2024, which is 2005.45% down from last year.
- Per Axsome Therapeutics' latest filing, its EBIAT stood at -$47.2 million for Q3 2025, which was up 2689.24% from -$48.0 million recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' EBIAT ranged from a high of -$11.2 million in Q1 2023 and a low of -$98.7 million during Q4 2023
- Its 4-year average for EBIAT is -$57.9 million, with a median of -$61.2 million in 2022.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 7169.46% in 2023, then crashed by 50935.1% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' EBIAT stood at -$61.2 million in 2022, then crashed by 61.09% to -$98.7 million in 2023, then grew by 24.06% to -$74.9 million in 2024, then surged by 36.95% to -$47.2 million in 2025.
- Its EBIAT was -$47.2 million in Q3 2025, compared to -$48.0 million in Q2 2025 and -$59.4 million in Q1 2025.